Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Biomarkers for the early stages of clinical development in Alzheimer's disease.

Bordet R, Dartigues JF, Dubois B, Goehrs JM, Vernoux L, Semah F, Pasquier F, Bidaut-Mazel C; participatnts of Round Table n°3 if Giens XXV.

Therapie. 2010 Jul-Aug;65(4):285-90, 277-283. doi: 10.2515/therapie/2010040. Epub 2010 Sep 21. Review. English, French.

PMID:
20854749
2.

Biomarqueurs aux phases précoces de développement dans la maladie d'Alzheimer.

Bordet R, Dartigues JF, Dubois B, Goehrs JM, Vernoux L, Semah F, Pasquier F, Bidaut-Mazel C; les participants à la Table Ronde n°3 de Giens XXV.

Therapie. 2010 Jul-Aug;65(4):277-83. doi: 10.2515/therapie/2010039. French. No abstract available.

PMID:
27393108
3.

Endpoints for trials in Alzheimer's disease: a European task force consensus.

Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G; European Task Force Group.

Lancet Neurol. 2008 May;7(5):436-50. doi: 10.1016/S1474-4422(08)70087-5. Review. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
18420157
4.

Influence of the behaviour pattern on the nocebo response of healthy volunteers.

Drici MD, Raybaud F, De Lunardo C, Iacono P, Gustovic P.

Br J Clin Pharmacol. 1995 Feb;39(2):204-6.

5.

[Tamoxifen-acenocoumarol interaction. A potentially dangerous interaction].

Gustovic P, Baldin B, Tricoire MJ, Chichmanian RM.

Therapie. 1994 Jan-Feb;49(1):55-6. French. No abstract available.

PMID:
8091371
6.

[Risk related to withdrawal from non-psychotropic drugs].

Chichmanian RM, Gustovic P, Spreux A, Baldin B.

Therapie. 1993 Sep-Oct;48(5):415-9. French.

PMID:
8146817

Supplemental Content

Loading ...
Support Center